Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4867)	10/31/2001 2:05:13 PM
From: tuck	Respond to of 52153

This Frost & Sullivan PR about the melanoma market also contains a little general color about the pace at the FDA: still slow. >>SAN JOSE, Calif., Oct. 31 /PRNewswire/ -- The incidence rate of melanoma is climbing annually, particularly in young adults. Surgery is successful with early detection, but the risk of recurrence in other patients is high and the chances of survival in those with advanced disease are bleak. According to a new analysis by Frost & Sullivan (www.pharma.frost.com ) of the U.S. Emerging Melanoma Therapeutics Markets, revenues for chemotherapeutics could rise from $20.3 million in 2000 to $119.8 million in 2007. Immunotherapeutics revenues are projected to grow from $68.7 million in 2000 to $973.4 million in 2007. ``There is a growing need for new drugs that prevent relapse, slow disease progression and improve survival rates, and do so with minimal side effects,'' says Frost & Sullivan Industry analyst Theresa O'Connell. ``The trend toward immunotherapeutics will play a dominant role in the expected transformation of the melanoma market over the next ten years'' Immunotherapeutic products are more target-specific and therefore elicit fewer and less severe side effects than conventional chemotherapeutics. Unfortunately, high FDA standards and an approval backlog could slow deployment of these products. ``Despite efforts by the FDA to accelerate the drug approval process, the backlog of new drug applications and biologics license applications, awaiting regulatory approval is growing,'' says O'Connell. ``Many industry participants believe that the FDA has raised the bar for drug approval.'' The FDA's meticulous approach to approving the first melanoma cancer vaccines is significantly delaying the introduction of these novel therapeutics and could restrain market growth. Frost & Sullivan presents the 2001 Marketing Engineering Awards to companies that have worked diligently to make a positive contribution to the emerging melanoma therapeutics industry. These market-specific awards are presented to: Corixa Corporation, Genzyme Molecular Oncology, Protarga, Inc., and Therion Biologics Corporation. The following is a list of key industry participants: Antigenics; AVAX Technologies, Inc.; Bayer Pharmaceuticals, Inc.: Bristol-Myers Squibb, Inc.; CancerVax Corp.; Celgene Corp.; Chiron Corp.; Corixa Corp; Cytran, Inc.; EntreMed, Inc.; Enzon Inc.; Genta, Inc.; Genzyme Molecular Oncology; ImClone Systems Inc.; Immunex Corp.; Maxim Pharmaceuticals; MGI Pharma, Inc.; Progenics Pharmaceuticals; Inc.; Protarga; Schering-Plough; Shire Pharmaceutical Group Plc; SuperGen; Therion Biologics Corporation; Titan Pharmaceuticals, Inc.; Tularik, Inc.; Valentis, Inc.; and Vical, Inc. Frost & Sullivan is a global leader in strategic market consulting and training. This ongoing research is part of the Pharmaceutical Subscription, which also includes market analyses on U.S Prostate Cancer and U.S. Emerging Lung Cancer Therapeutics Market. Frost & Sullivan also offers custom consulting to a variety of national and international companies. Interviews are available to the press. U.S. Emerging Melanoma Therapeutics Markets Report: A090-52 Contact: Kristi Grier P: 210.247.2403 F: 210.348.1003 Fax E: kgrier@frost.com www.frost.com SOURCE: Frost & Sullivan<< Cheers, Tuck